Stock 2181 MABPHARM LIMITED
Add to a list

Mabpharm Limited Stock

Stocks

2181

KYG5780F1046

Biotechnology & Medical Research

Market Closed - Hong Kong S.E.
Other stock markets
 12:08:52 29/06/2026 +04 		5-day change 1st Jan Change
0.4200 HKD 0.00% Intraday chart for Mabpharm Limited +10.53% -16.00%
06-09 Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration CI
06-09 Mabpharm's Application for Osteoporosis Drug Approved in China MT

Valuation: Mabpharm Limited

Market Cap 1.5B 1.73B 221M 193M 179M 167M 314M 20.88B 321M 2.15B 829M 10.3B 829M 811M 35.76B P/E 2024
-8.48x
P/E 2025 44.9x
Enterprise Value 1.72B 1.98B 253M 221M 204M 191M 359M 23.9B 367M 2.46B 949M 11.79B 950M 929M 40.94B EV / Sales 2024
5.06x
EV / Sales 2025 3.2x
Free-Float
22.82%
Yield 2024 *
-
Yield 2025 -
* Estimated data More valuation ratios

Chart: Mabpharm Limited

Dynamic Chart

Latest news : Mabpharm Limited

06-09 Mabpharm Limited Receives Approval For New Drug Application Of CMAB807 Denosumab Injection From National Medical Products Administration CI
06-09 Mabpharm's Application for Osteoporosis Drug Approved in China MT
03-26 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2025 CI
03-26 Mabpharm FY profit and total comprehensive income attributable rmb57.1 million RE
12-05 Mabpharm Limited Announces Change of Address of Principal Place of Business in Hong Kong CI
31/10/25 Mabpharm Limited Announces Board and Committee Changes, Effective October 31, 2025 CI
28/08/25 Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2025 CI
27/03/25 Mabpharm Shrinks Loss by 39% in 2024 MT
26/03/25 Mabpharm Limited Reports Earnings Results for the Full Year Ended December 31, 2024 CI
03/01/25 Mabpharm's Infliximab Drug Receives Approval from Pakistan's Drug Regulator MT
02/01/25 Mabpharm Limited Announces Approval from the Drug Regulatory Authority of Pakistan on the Registration of Core Product, CMAB008 (Infliximab for Injection) CI
27/12/24 Mabpharm Limited Announces Approval from the Indonesian National Agency of Drug and Food Control on the Marketing Authorization of its Core Product, CMAB008 (Infliximab for Injection) CI
28/08/24 Mabpharm Limited Reports Earnings Results for the Half Year Ended June 30, 2024 CI
More news

Press Releases: Mabpharm Limited

13/11/23 Cryopyrin-Associated Periodic Syndrome Pipeline, Clinical Trials Studies, Emerging Drugs, Mergers and Acquisition, Licensing, Agreements & Collaborations, and Latest News 2023 (Updated) AQ
20/07/21 Mabpharm : Sorrento Announces Its Partner Mabpharm Has Received Marketing Approval In China For Infliximab Biobetter AQ
30/04/21 Mabpharm : POLL RESULTS OF THE EXTRAORDINARY GENERAL MEETING HELD ON FRIDAY, APRIL 30, 2021 PU
21/04/21 Mabpharm : FORM OF PROXY FOR THE ANNUAL GENERAL MEETING TO BE HELD ON FRIDAY, JUNE 18, 2021 PU
12/04/21 Mabpharm : (1) DISCLOSEABLE AND CONNECTED TRANSACTION IN RELATION TO THE ACQUISITION OF CMAB807 (2) CONTINUING CONNECTED TRANSACTIONS IN RELATION TO THE CLINICAL TRIALS AGREEMENT AND THE CDMO AGREEMENT AND (3) NOTICE OF EXTRAORDINARY GENERAL MEETING PU
More press releases

Quotes and Performance

1 week+10.53%
Current month+6.33%
1 month+5.00%
3 months-23.64%
6 months-22.22%
Current year-16.00%
More quotes

Course Extremes

1 week 0.41
Extreme 0.41
 0.45
1 month 0.31
Extreme 0.31
 0.51
Current year 0.31
Extreme 0.31
 0.81
1 year 0.31
Extreme 0.31
 0.88
3 years 0.25
Extreme 0.25
 0.94
5 years 0.25
Extreme 0.25
 1.4
10 years 0.25
Extreme 0.25
 1.8
More quotes

Managers and Directors: Mabpharm Limited

Manager TitleAgeSince
Hao Wang CEO
 Chief Executive Officer 57 28/10/2020
Sheng Hou PRN
 Corporate Officer/Principal 49 01/12/2023
Jing Tao PRN
 Corporate Officer/Principal 53 03/08/2018
Director TitleAgeSince
Hao Wang BRD
 Director/Board Member 57 20/07/2018
Yun Feng Li BRD
 Director/Board Member 49 20/07/2018
Shu Ge Jiao CHM
 Chairman 60 20/07/2018
More insiders

Latest insider transactions

Date Insider Type Main position Quantity % Market Cap.
10/02/23
Jing Tao
Other

Director

75,192 0.0018%
Transaction History

Bio Therapeutic Drugs

Add to a list

0 selected

To use this feature you must be a member
Log inSign up
 Change 5-day change 1-year change 3-year change Capi.($)
MABPHARM LIMITED Stock Mabpharm Limited
0.00%+10.53%-13.40%-25.00% 221M
ARGENX SE Stock argenx SE
+0.13%-1.33%+67.18%+121.93% 55.63B
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
+6.76%+22.83%+91.66%+101.42% 52.25B
BIONTECH SE Stock BioNTech SE
+1.74%+2.92%-12.82%-13.25% 23.07B
INSMED INCORPORATED Stock Insmed Incorporated
+0.81%+5.76%+3.62%+413.19% 22.41B
WUXI BIOLOGICS (CAYMAN) INC. Stock WuXi Biologics (Cayman) Inc.
+6.78%+14.47%+40.28%-6.67% 17.32B
GENMAB A/S Stock Genmab A/S
+0.97%+3.81%+30.68%-32.21% 15.94B
EXELIXIS, INC. Stock Exelixis, Inc.
-0.11%+7.45%+25.18%+191.01% 13.77B
PHARMAESSENTIA CORPORATION Stock PharmaEssentia Corporation
+9.96%+19.81%+157.65%+320.70% 13.47B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD. Stock Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
+4.21%+4.76%+33.21% - 12.43B
Average +3.12%+7.21%+42.32%+119.01% 22.65B
Weighted average by Cap. +3.25%+7.62%+54.65%+127.75%
See all sector performances

Financials

2024 2025
Net sales 258M 298M 37.99M 33.26M 30.71M 28.67M 53.98M 3.59B 55.2M 369M 143M 1.77B 143M 140M 6.15B 646M 745M 95.04M 83.22M 76.83M 71.74M 135M 8.99B 138M 925M 357M 4.43B 357M 349M 15.39B
Net income -128M -148M -18.82M -16.48M -15.21M -14.21M -26.74M -1.78B -27.35M -183M -70.68M -878M -70.68M -69.13M -3.05B 57.13M 65.92M 8.4M 7.36M 6.79M 6.34M 11.94M 795M 12.21M 81.75M 31.56M 392M 31.56M 30.87M 1.36B
Net Debt 222M 256M 32.69M 28.63M 26.43M 24.68M 46.45M 3.09B 47.51M 318M 123M 1.52B 123M 120M 5.29B 217M 251M 31.99M 28.01M 25.86M 24.15M 45.46M 3.02B 46.49M 311M 120M 1.49B 120M 118M 5.18B
* Estimated data More financial data

Company Profile

Logo Mabpharm Limited
Mabpharm Ltd is an investment holding company primarily engaged in the research, development and production of monoclonal antibody drugs for cancers and autoimmune diseases. The Company’s main products include CMAB009 Enlituo (cetuximab β injection), CMAB007 Aomaishu (Omalizumab α for Injection), CMAB008 Leiting (infliximab for injection) and other products. The Company’s products are mainly used for colorectal cancer, asthma, urticaria, rheumatoid arthritis, ulcerative colitis in adults and other diseases. The Company is also engaged in the transfer of intellectual property. The Company mainly conducts its business in the domestic market.
Employees
389
Sector
Biotechnology & Medical Research
More about the company

Quotes

Date Price Change Volume
29/06/26 HK$0.4200 0.00% 0
26/06/26 HK$0.4200 -4.55% 554,000
25/06/26 HK$0.4400 0.00% 0
24/06/26 HK$0.4400 +7.32% 406,000
23/06/26 HK$0.4100 0.00% 22,000

Delayed Quote Hong Kong S.E.

More quotes

Income Statement and Estimates

More financial data
  1. Stock Market
  2. Stocks
  3. 2181 Stock

Select your edition

All financial news and data tailored to specific country editions

NORTH AMERICA

MarketScreener
United-States
MarketScreener Canada
Canada

MIDDLE EAST

MarketScreener Saudi Arabia
Saudi Arabia
MarketScreener UAE Emirates
United Arab Emirates

EUROPE

Zonebourse
France
MarketScreener Deutschland
Deutschland
Zonebourse Suisse
Suisse
MarketScreener Schweiz
Schweiz
MarketScreener Italia
Italia
MarketScreener Österreich
Österreich
MarketScreener België
België
MarketScreener Nederland
Nederland
MarketScreener España
España
MarketScreener Sverige
Sverige
MarketScreener UK
United Kingdom

APAC

MarketScreener Australia
Australia
MarketScreener India
India
MarketScreener Hong Kong
Hong Kong